CTOs on the Move

NeuroBo Pharmaceuticals

www.neurobopharma.com

 
NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeuroBo Pharmaceuticals raised $10M on 01/19/2021

Similar Companies

SSPCC

SSPCC, Inc. is a Phoenixville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neighborhood Health Center of WNY

Impactful healthcare provided by kind people so Western New Yorkers can achieve their dreams and goals. Quality care, regardless of ability to pay. #unstoppable

SemBioSys Genetics

SemBioSys Genetics is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saluda Medical

Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed to maintain individualized, consistent therapy by precisely controlling spinal cord activation through real-time customization of waveforms on every evoked compound action potential (ECAP) at the same rate as the stimulation frequency (At stimulation frequency of 40 Hz, 40 adjustments are made each second, 3`5 million adjustments per day, and 1`2 billion adjustments per year)`

Black Diamond Therapeutics

Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery Engine in Basel, Switzerland.